Activin and Inhibin

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.In VivoDMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2105 (Compound 7k) shows 74 and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2105

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2105 (Compound 7k) shows 74 and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2105

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2105 (Compound 7k) shows 74 and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2105

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2105 (Compound 7k) shows 74 and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2105

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2105 (Compound 7k) shows 74 and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2105

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2139 (6j) shows 88 and 133-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2139, the EC 50 is

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2139 (6j) shows 88 and 133-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2139, the EC 50 is

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2139 (6j) shows 88 and 133-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2139, the EC 50 is

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2139 (6j) shows 88 and 133-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2139, the EC 50 is

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC 50 s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.In VitroDMU2139 (6j) shows 88 and 133-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2. In the presence of DMU2139, the EC 50 is